NDC product
Voriconazole
NDC 0121-1091 · PAI Holdings, LLC dba PAI Pharma
Key facts
| Product NDC | 0121-1091 |
|---|---|
| Proprietary name | Voriconazole |
| Nonproprietary name | Voriconazole Injection |
| Substances | VORICONAZOLE |
| Dosage form | INJECTION |
| Route | INTRAVENOUS |
| Labeler | PAI Holdings, LLC dba PAI Pharma |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA220043 |
| Pharmacologic classes | Azole Antifungal [EPC], Azoles [CS], Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 2C9 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA] |
| Marketing start | May 14, 2026 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: